Scarica l'app Stockscreener
22.01
5.01%
1.05
Dopo l'orario di chiusura:
22.44
0.43
+1.95%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$20.96
Aprire:
$21.4
Volume 24 ore:
2.31M
Relative Volume:
1.45
Capitalizzazione di mercato:
$3.75B
Reddito:
$1.07B
Utile/perdita netta:
$391.00M
Rapporto P/E:
9.6181
EPS:
2.2884
Flusso di cassa netto:
$6.31M
1 W Prestazione:
+8.32%
1M Prestazione:
-11.85%
6M Prestazione:
+3.77%
1 anno Prestazione:
+28.64%
Intervallo 1D:
$21.40
$22.36
Intervallo di 1 settimana:
$19.89
$22.36
Portata 52W:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.01 | 3.57B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-23 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback - Proactive financial news
Acadia Pharmaceuticals (ACAD) Upgraded to Buy by BofA - GuruFocus
Acadia Pharma upgraded at BofA following stock pullback - MSN
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback - TipRanks
ACAD: B of A Securities Upgrades ACADIA Pharmaceuticals Rating t - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Raised to "Buy" at Bank of America - MarketBeat
BofA upgrades Acadia Pharmaceuticals stock rating on valuation By Investing.com - Investing.com Canada
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Hudson Bay Capital Management LP Sells 119,700 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Market Recap: How does ACADIA Pharmaceuticals Inc compare to its peersBreakout Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Hedge Fund Moves: How does ACADIA Pharmaceuticals Inc compare to its peersProfit Target & Long-Term Safe Investment Plans - baoquankhu1.vn
Aug Outlook: Does ACADIA Pharmaceuticals Inc offer margin of safety2026 Analyst Calls & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Acadia (NASDAQ: ACAD) director receives new option and RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director Jonathan Poole submits initial Form 3 insider report - Stock Titan
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - MSN
Mizuho upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Oppenheimer maintains a balanced outlook on ACADIA Pharmaceuticals Inc. (ACAD) for 2026 - MSN
Wolfe Research notes conviction-driven opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains - MSN
ACADIA Pharmaceuticals invites engagement at major pediatric event - Traders Union
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News & Headlines - Yahoo Finance
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year - Yahoo Finance
ACADIA Pharmaceuticals at Stifel CNS Forum: Strategic Insights Unveiled - Investing.com India
ACADIA Pharmaceuticals at Stifel CNS Forum: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Algert Global LLC Has $8.54 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
(ACAD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett ReviewWhat's Changed - simplywall.st
Acadia Pharmaceuticals annual revenue surpasses 1 billion dollars at Nasdaq bell ceremony - Traders Union
Acadia Pharmaceuticals Rings the Opening Bell - Nasdaq
Acadia Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Fred Alger Management LLC Sells 820,421 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness - Yahoo Finance
Braidwell LP Makes New $50.76 Million Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals confirms role at Stifel 2026 Virtual CNS Forum - Traders Union
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors? - simplywall.st
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP - MarketBeat
ACADIA Pharmaceuticals unveils new Rett Syndrome research at Baltimore genetics meeting - Traders Union
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - The AI Journal
Acadia Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth and Innovations - Investing.com India
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead - MarketBeat
Equity grants for ACADIA (ACAD) principal accounting officer - Stock Titan
Acadia (ACAD) CFO receives new stock options and RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) awards options and RSUs to Chief Commercial Officer - Stock Titan
Acadia (NASDAQ: ACAD) EVP awarded large stock option and RSU grants - Stock Titan
Acadia Pharmaceuticals (ACAD) grants CEO large options and RSUs - Stock Titan
ACADIA Pharmaceuticals to exhibit at ACMG event in Baltimore - Traders Union
ACADIA Pharmaceuticals (ACAD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
ACAD plans re-examination after CHMP rejects Rett syndrome drug in EU (revised) - MSN
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome - Sahm
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):